Supramolecular Peptide Nanostructures for Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering sodium channel blockers, such as tetrodotoxin, face challenges in achieving controlled and sustained release, leading to rapid diffusion and potential overdose risks due to lack of effective delivery systems.
Innovation Solution
The development of supramolecular nanostructures composed of peptide moieties with specific sodium channel peptide sequences and hydrophobic domains that form nanofibers, allowing for controlled release of sodium channel blockers by facilitating cooperative binding and prolonged retention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery methods are used for sodium channel blockers, then the drug can be administered, but rapid diffusion occurs leading to loss of control and potential overdose
Solution Approach 1:
The patent embeds the sodium channel blocker within the supramolecular nanostructure, creating a nested system where the drug is contained within the peptide-based framework. This nesting mechanism allows controlled release by preventing rapid diffusion while maintaining therapeutic efficacy, directly resolving the contradiction between control and diffusion rate.
Solution Approach 2:
The supramolecular nanostructure acts as an intermediary between the drug and the biological target. It mediates the delivery process by controlling the release kinetics, preventing direct rapid diffusion into the bloodstream while still enabling targeted delivery to sodium channels, thus improving control over the release speed.
2Reliability
If frequent dosing is used to maintain therapeutic levels, then efficacy is improved, but the risk of overdose increases and patient compliance decreases
Solution Approach 1:
The supramolecular nanostructure enables continuous and sustained release of the sodium channel blocker over extended periods. This continuity of useful action eliminates the need for frequent dosing while maintaining therapeutic efficacy, thereby reducing overdose risk and improving patient compliance without compromising treatment effectiveness.
3Duration of action of stationary object
If peptide sequences are designed to bind sodium channel blockers, then retention is improved, but the complexity of designing and synthesizing the supramolecular structures increases
Solution Approach 1:
The patent segments the peptide structure into distinct functional domains: hydrophobic regions for self-assembly and hydrophilic regions for drug binding. This segmentation simplifies the design process by allowing independent optimization of each domain while achieving prolonged retention through cooperative binding, thus reducing overall design and synthesis complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The supramolecular nanostructures enable a controlled and sustained release of sodium channel blockers, reducing the frequency of dosing and minimizing the risk of overdose by maintaining the peptides in close proximity for extended periods, thereby enhancing the therapeutic efficacy and safety.
Implementation Method 1
the first hydrophobic domain is associated with the second hydrophobic domain via a hydrophobic interaction
Data Source
AI summary
Compositions and methods for the administration of active agents are generally described. In some embodiments, compositions comprising peptide moieties are described. The peptide moieties may comprise sodium channel peptide sequences, such as TQDYWEN (SEQ ID NO: 1) and/or CGEWIET (SEQ ID NO: 2). According to certain embodiments, the peptide moieties are connected to a hydrophobic domain. The presence of both the peptide moiety and the hydrophobic domain may drive self-assembly (e.g., to form a supramolecular nanostructure). The supramolecular nanostructure may facilitate cooperative interaction between distinct peptide sequences. In some embodiments, the peptide sequences bind to the active agents. Binding between the active agent and the peptide sequences may advantageously facilitate controlled release of the active agent. In the context of the present disclosure, it has been inventively recognized that drug delivery may be improved through the use of compositions and methods described herein below.